Revolution Medicines officer sells 1,774 shares

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported that Chief Global Commercialization Officer Anthony Mancini sold a total of 1,774 shares of common stock on September 16, 2026 in open-market transactions under a Rule 10b5-1 trading arrangement adopted on June 15, 2026 to satisfy tax withholding on vesting restricted stock units.

The sales were executed at weighted average prices of $195.05 and $199.30 per share across narrow price ranges, and Mancini continues to hold equity awards, including 39,575 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 1,774 shares

Net Sell 2 txns

Insider Mancini Anthony

Role See Remarks

Sold 1,774 shs ($353K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	27	$195.0521	$5K
Sale	Common Stock F1, F3	1,747	$199.3032	$348K

Holdings After Transaction: Common Stock — 42,116 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
2. F2. The transaction was executed in multiple trades at prices ranging from $195.03 to $195.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. Includes 39,575 restricted stock units.

Key Figures

Shares sold (total): 1,774 shares First tranche shares sold: 27 shares First tranche weighted average sale price: $195.05 per share +4 more

7 metrics

Shares sold (total) 1,774 shares Total common shares sold on September 16, 2026

First tranche shares sold 27 shares Common stock sold on September 16, 2026

First tranche weighted average sale price $195.05 per share Weighted average; trades ranged from $195.03 to $195.07

Second tranche shares sold 1,747 shares Common stock sold on September 16, 2026

Second tranche weighted average sale price $199.30 per share Weighted average sale price for second transaction

Restricted stock units held 39,575 units Restricted stock units included in post-transaction holdings

Rule 10b5-1 plan adoption date June 15, 2026 Instruction letter for sales to satisfy RSU tax withholding

Key Terms

Rule 10b5-1, restricted stock units, weighted average sale price, tax withholding obligation

4 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock units financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price"

tax withholding obligation financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD report for Anthony Mancini?

Revolution Medicines reported that Anthony Mancini sold 1,774 shares of RVMD common stock on September 16, 2026 in open-market transactions under a Rule 10b5-1 trading arrangement to satisfy tax withholding on vesting restricted stock units.

At what prices were the RVMD shares sold by Anthony Mancini?

The reported sales were executed at weighted average prices of $195.05 per share for 27 shares and $199.30 per share for 1,747 shares, within narrow price ranges disclosed in the filing’s footnotes.

How many Revolution Medicines (RVMD) shares did Anthony Mancini sell in total?

Anthony Mancini sold a total of 1,774 shares of Revolution Medicines common stock, consisting of 27 shares in one transaction and 1,747 shares in a second transaction on September 16, 2026.

Was the RVMD insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5-1 instruction letter adopted on June 15, 2026 to address the reporting person’s tax withholding obligation upon the vesting of restricted stock units.

Does Anthony Mancini still hold RVMD equity after these transactions?

Yes. The filing notes that Mancini’s holdings include 39,575 restricted stock units after the reported transactions, indicating he continues to hold a significant equity-based position in Revolution Medicines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 06:05 PM Accepted by SEC EDGAR 09/18/2026 - 06:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Anthony

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		27	D	$195.0521(2)	43,863	D
Common Stock	09/16/2026		S(1)		1,747	D	$199.3032	42,116(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

2. The transaction was executed in multiple trades at prices ranging from $195.03 to $195.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 39,575 restricted stock units.

Remarks:

Chief Global Commercialization Officer

	/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)